Long lasting BCG protection against leprosy

Laura Cunha Rodrigues a,*, Ligia Regina Sansigolo Kerr-Pontes b, Max Victor Carioca Frietas c, Maurício Lima Barreto d

a Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK
b Departamento de Saúde Comunitária, Faculdade de Medicina, Universidade Federal do Ceará, Brazil
c Departamento de Imunologia, Faculdade de Medicina, Universidade Federal do Ceará, Brazil
d Instituto de Saúde Coletiva, Universidade Federal da Bahia, Brazil

Received 25 November 2006; received in revised form 5 June 2007; accepted 19 July 2007
Available online 6 August 2007

Abstract

Background: BCG vaccine protects against leprosy.
Objectives: Estimate BCG protection against leprosy by age by age.
Methods: A case control study with 226 cases of leprosy and 857 controls. BCG vaccination was ascertained via examination of BCG scars. Protection is presented for three age groups.
Results: BCG protection against leprosy was 86% (95% CI: 77–92%) in the age group 18–29; 54% (95% CI: −37% to 85%) in the age group 30–39 and 32% (95% CI: −3% to 56%) in those aged 40 or more.
Conclusions: BCG efficacy against leprosy may well last for three decades and possibly even longer. BCG vaccination must have contributed to worldwide reduction in leprosy incidence.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: BCG vaccine; Leprosy; Waning of protection; Duration of protection; Vaccine efficacy

1. Background

Leprosy is an infectious, chronic disease caused by Mycobacterium leprae. New infections still occur in Africa, Asia and Latin America. WHO reports that in 2005 there were 286,063 prevalent cases worldwide, with 407,791 new cases detected in 2004. Of the new cases detected, about 10% were in children, and just under 5% had a severe disability caused by the leprosy. Brazil has a high prevalence (4 per 10,000 inhabitants) and 10% of the newly detected cases in the world are detected there [1]. BCG vaccination prevents mycobacterial diseases, including leprosy and tuberculosis. Neonatal BCG vaccination is routinely used in most of the world, including Brazil, to prevent tuberculosis. Intra dermal BCG vaccination replaced oral BCG vaccination in Brazil in 1972 [2]. Coverage rates for BCG have been close to 100% in the last 10 years. BCG also protects against leprosy. BCG is a complex vaccine: protection against tuberculosis is known to vary geographically; and against both tuberculosis and leprosy by form of disease. BCG protection wanes with time since vaccination. In fact until recently there was no evidence of BCG protection against tuberculosis lasting more than 10 years [3]. In the past 2 years, there have been three reports of much longer duration of BCG protection, two against tuberculosis [4,5] and one against leprosy [6]. The present paper reports on the protection by age, presumed to reflect protection by time since vaccination offered by BCG against leprosy in a case control study in Brazil.

2. Methods

Methods of the case control study have been published elsewhere [7] but in short, the study was conducted in four municipalities in the state of Ceará, in Northeast Brazil. Cases
were adults (over 18) notified with leprosy in the 2 years before the study, who had one of (a) characteristic skin lesion with loss of sensitivity or (b) nerve thickening with loss of sensitivity or (c) M. leprae at bacilloscopy examination at the reference laboratory (LACEN-CE). Cases were classified according to Ridley and Jopling classification based on the information on the treatment records. All eligible subjects presenting at the health facility for leprosy treatment between March and August 2002 were invited to participate in the study. Four controls per cases were selected from individuals who lived in the same municipality and were aged over 18 presenting to the same health facility for complaints other than skin diseases. Because the original study was investigating novel sources of infection, cases and controls were excluded if they were contacts of a known leprosy case. Cases (226) and controls (857) answered a questionnaire about past exposures, socio-economic environmental and behavioural factors. Of particular interest for this analysis, previous BCG was ascertained by examination of the upper arm for presence of a BCG scar and by history. Analytical methods used and results of the original case control study were described elsewhere [7] but in short, a conditional logistic model was used to investigate the effect of socio-economic, environmental, behavioural, and demographic variables, and of BCG. In the final model the following variables were statistically significant: education, frequency of changing bed linen, history of bathing in open water bodies, and having experienced poverty such that they had had to go without food. Previous BCG vaccination was protective \( (OR = 0.48) \), corresponding to a vaccine effectiveness of 52%. Because of the clear BCG protection in adults in the main study we undertook the analysis reported in this paper to investigate BCG protection by age (and indirectly duration of protection). This consisted of repeating the final conditional logistic regression model (including the same variables as the final model above) separately for three age groups: 18–29; 30–39; and 40 and over. Validity of BCG scar reading was estimated comparing presence of scar (the gold standard) with reported information on BCG vaccination, for all groups together and separately for the older age group. The study was approved by the Ethical Committee of the Federal University of Ceará.

### 3. Results

Table 1 presents validity of scar reading. Overall specificity was 90% (95% CI: 86–92%) and sensitivity: 98% (95% CI: 96–99%). For those 40 years or older, the specificity was 83% (95% CI: 77–88%) and the sensitivity was 99% (95% CI: 98–100%). The proportion of controls who had BCG vaccination (which should reflect to a certain degree BCG vaccine coverage in that age cohort) was 81% in those aged under 30; 71% in those aged 30–39 and 32% in those aged over 40. Table 2 presents the number of cases and controls with and without BCG scar for each of the three age groups. Adjusted estimates of BCG efficacy were 86% (95% CI: 77–92%) in the younger age group; 54% (95% CI: −37% to 85%) in the age group 30–39 and 32% (95% CI: −3% to 56%) in the older age group.

### 4. Discussion

Our results show significant BCG protection against leprosy up to age 30, and an intriguing potential for protection at later ages, although evidence so far is weak. Scar had been shown before to be an excellent indicator of intradermal BCG vaccination in Brazil [8]; this was confirmed in this study. It is unlikely that using scars to indicate previous vaccination introduced errors.

We found that BCG gave very high protection against leprosy (86%) up to age 29. This estimate of protection is well within the range of protection found in three studies undertaken in different states in Brazil in the past: 74% in Manaus, in the North; [9] 81% in States in Central Brazil [10] and 90% in Sao Paulo, in the South [11]. Can we assume that the large majority of vaccinations were given at birth and therefore protection at age up to 29 years corresponds to duration of protection for 29 years? The answer is probably yes for this age group. The National Tuberculosis Control Program introduced neonatal BCG vaccination in Brazil in 1972 [2] and reached very high coverage as the State had a very strong public funded well baby programme with free health care and vaccination. Some of these subjects might have received a second dose: from to 1995 to 2006 the National Tuberculosis Control Program recommended revaccination at ages 7–14; the study did not note the number of scars, only presence or absence. However, the programme was controversial and the coverage for the second dose in the state was very low. So it is very likely that the very high protection observed at ages up to 29 reflects duration of protection for at least 29 years. Until recently, there was no evidence of duration of BCG protection for more than 10 years. Recently two studies reported long lasting protection against tuberculosis mortal-

<table>
<thead>
<tr>
<th>Age</th>
<th>BCG scar N (%)</th>
<th>Adjusted VE (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Cases</td>
</tr>
<tr>
<td>18–29</td>
<td>184(81)</td>
<td>19(44)</td>
</tr>
<tr>
<td>30–39</td>
<td>119(71)</td>
<td>14(44)</td>
</tr>
<tr>
<td>40 or +</td>
<td>148(32)</td>
<td>37(25)</td>
</tr>
</tbody>
</table>

### Table 1

Specificity and sensitivity of scar reading as an indication of BCG vaccination as reported

<table>
<thead>
<tr>
<th>BCG Scar</th>
<th>Reported BCG vaccination</th>
<th>Reported no BCG vaccination</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG Scar</td>
<td>435</td>
<td>51</td>
<td>486</td>
</tr>
<tr>
<td>No BCG scar</td>
<td>11</td>
<td>481</td>
<td>492</td>
</tr>
<tr>
<td>Total</td>
<td>446</td>
<td>532</td>
<td>978</td>
</tr>
</tbody>
</table>

### Table 2

Cases and controls according to BCG scar and age
but again this would not have an impact in this study as BCG was given. Age has an impact on the immune system; this decay is present in innate and in adaptive immune response [12]. Is it possible that having received BCG can reduce this decay? This is consistent with the role of BCG in stimulating interferon production, and would explain both this finding and the lower mortality by tuberculosis 50 years after BCG vaccination in the trial in the USA.

Finally, this was a case control study and as such potentially subject to bias. Recall bias is unlikely as scar was examined and validity of scar was so high. This adds to the new and growing evidence that BCG protection against tuberculosis and leprosy can last much longer than previously believed. Finally, adults over 40 with a BCG scar may have lower risk of leprosy, and further research should investigate potential mechanism for that protection.

Acknowledgements

The authors acknowledge the CNPq (#620168/2004-8) and CAPES (#0119/01-6) for supporting this project.

References